151 related articles for article (PubMed ID: 36837431)
1. Validation of a New Prognostic Score in Patients with Ovarian Adenocarcinoma.
Trifanescu OG; Mitrica RI; Gales LN; Marinescu SA; Motas N; Trifanescu RA; Rebegea L; Gherghe M; Georgescu DE; Serbanescu GL; Bashar HH; Dragosloveanu S; Cristian DA; Anghel RM
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837431
[No Abstract] [Full Text] [Related]
2. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
Okunade KS; Dawodu O; Adenekan M; Nwogu CM; Awofeso O; Ugwu AO; Salako O; John-Olabode S; Olowoselu OF; Anorlu RI
Niger J Clin Pract; 2020 Aug; 23(8):1141-1147. PubMed ID: 32788493
[TBL] [Abstract][Full Text] [Related]
4. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
5. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
Landrum LM; Java J; Mathews CA; Lanneau GS; Copeland LJ; Armstrong DK; Walker JL
Gynecol Oncol; 2013 Jul; 130(1):12-8. PubMed ID: 23578540
[TBL] [Abstract][Full Text] [Related]
7. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
8. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
Zhou M; Li L; Wang X; Wang C; Wang D
Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: A single-center experience.
Liu Y; Cao L; Chen W; Wang J; Wang W; Liang Z
Medicine (Baltimore); 2020 Sep; 99(36):e22100. PubMed ID: 32899091
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.
Canzler U; Lück HJ; Neuser P; Sehouli J; Burges A; Harter P; Schmalfeldt B; Aminossadati B; Mahner S; Kommoss S; Wimberger P; Pfisterer J; de Gregorio N; Hasenburg A; Gropp-Meier M; El-Balat A; Jackisch C; du Bois A; Meier W; Wagner U
Arch Gynecol Obstet; 2020 May; 301(5):1267-1274. PubMed ID: 32277253
[TBL] [Abstract][Full Text] [Related]
12. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Garcia-Soto AE; Java JJ; Nieves Neira W; Pearson JM; Cohn DE; Lele SB; Tewari KS; Walker JL; Alvarez Secord A; Armstrong DK; Copeland LJ
Gynecol Oncol; 2016 Dec; 143(3):484-489. PubMed ID: 27726923
[TBL] [Abstract][Full Text] [Related]
13. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
[TBL] [Abstract][Full Text] [Related]
15. Nomogram of Combining CT-Based Body Composition Analyses and Prognostic Inflammation Score: Prediction of Survival in Advanced Epithelial Ovarian Cancer Patients.
Wang X; Zhang C; Cao F; Wang CB; Dong JN; Wang ZH
Acad Radiol; 2022 Sep; 29(9):1394-1403. PubMed ID: 34955366
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
17. Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO.
Klar M; Hasenburg A; Hasanov M; Hilpert F; Meier W; Pfisterer J; Pujade-Lauraine E; Herrstedt J; Reuss A; du Bois A
Eur J Cancer; 2016 Oct; 66():114-24. PubMed ID: 27561452
[TBL] [Abstract][Full Text] [Related]
18. Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis.
Ye Q; Cheng J; Ye M; Liu D; Zhang Y
J Gynecol Oncol; 2019 Jan; 30(1):e5. PubMed ID: 30479089
[TBL] [Abstract][Full Text] [Related]
19. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R
Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
